List of Figures
Figure 1: Comparison of Normal Human Hemoglobin and Hemoglobin S 6
Figure 2: Comparison of Shape and Flow of Normal Erythrocytes and Sickle Cells 7
Figure 3: Global Distribution of Sickle Cell Gene (HbS) and Malaria 8
Figure 4: Sickle cell anemia: Treatment overview 11
Figure 5: Hemoglobin Tetramer with a- and ß-Globulin Chains 12
Figure 6: Global Distribution of a- and ß-Thalassemia 14
Figure 7: Thalassemia: Treatment overview 16
Figure 8: HAE: Treatment overview 18
Figure 9: Sickle Cell Anemia, Total Market, Revenue Forecast ($m), 2011–2019 19
Figure 10: Sickle Cell Anemia, US, Revenue Forecast ($m), 2011–2019 20
Figure 11: Sickle Cell Anemia, UK, Revenue Forecast ($m), 2011–2019 20
Figure 12: Sickle Cell Anemia, France, Revenue Forecast ($m), 2011–2019 21
Figure 13: Sickle Cell Anemia, Germany, Revenue Forecast ($m), 2011–2019 21
Figure 14: Sickle Cell Anemia, Italy, Revenue Forecast ($m), 2011–2019 22
Figure 15: Sickle Cell Anemia, Spain, Revenue Forecast ($m), 2011–2019 22
Figure 16: Sickle Cell Anemia, Total Market, Average Annual Cost of Therapy, 2011–2019 23
Figure 17: Sickle Cell Anemia, Total Market, Treatment Usage Pattern (‘000), 2011–2019 24
Figure 18: Hydroxyurea Factsheet 25
Figure 19: Thalassemia, Total Market, Revenue Forecast ($m), 2011–2019 27
Figure 20: Thalassemia, US, Revenue Forecast ($m), 2011–2019 28
Figure 21: Thalassemia, UK, Revenue Forecast ($m), 2011–2019 28
Figure 22: Thalassemia, France, Revenue Forecast ($m), 2011–2019 29
Figure 23: Thalassemia, Germany, Revenue Forecast ($m), 2011–2019 29
Figure 24: Thalassemia, Italy, Revenue Forecast ($m), 2011–2019 30
Figure 25: Thalassemia, Spain, Revenue Forecast ($m), 2011–2019 30
Figure 26: Thalassemia, Japan, Revenue Forecast ($m), 2011–2019 31
Figure 27: Thalassemia, Total Market, Average Annual Cost of Therapy, 2011–2019 31
Figure 28: Thalassemia, Total Market, Treatment Usage Pattern 32
Figure 29: Hereditary Angioedema, Total Market, Revenue Forecast($m), 2011–2019 36
Figure 30: Hereditary Angioedema, US, Revenue Forecast ($m), 2011–2019 36
Figure 31: Hereditary Angioedema, UK, Revenue Forecast ($m), 2011–2019 37
Figure 32: Hereditary Angioedema, France, Revenue Forecast ($m), 2011–2019 37
Figure 33: Hereditary Angioedema, Germany, Revenue Forecast ($m), 2011–2019 38
Figure 34: Hereditary Angioedema, Italy, Revenue Forecast ($m), 2011–2019 38
Figure 35: Hereditary Angioedema, Spain, Revenue Forecast ($m), 2011–2019 39
Figure 36: Hereditary Angioedema, Japan, Revenue Forecast ($m), 2011–2019 39
Figure 37: Hereditary Angioedema, Total Market, Average Annual Cost of Therapy, 2011–2019 40
Figure 38: Hereditary Angioedema, Total Market, Treatment Usage Pattern 41
Figure 39: Inherited Orphan Blood Disorders: All Pipelines by Phase 44
Figure 40: Inherited Orphan Blood Disorders: All Pipelines by Phase and Route of Administration 45
Figure 41: Inherited Orphan Blood Disorders: All Pipelines by Phase and Molecule Type 46
Figure 42: Inherited Orphan Blood Disorders: All Pipelines by Mechanism of Action 47
Figure 43: Sickle Cell Anemia: Pipeline, Overview 48
Figure 44: Thalassemia: Pipeline, Overview 53
Figure 45: Hereditary Angioedema: Pipeline, Overview 57
Figure 46: Inherited Orphan Blood Diseases Market, Deal Segmentation by Year, 2000–2012 59
Figure 47: Inherited Orphan Blood Diseases Market, Deal Segmentation by Indication 59
Figure 48: Inherited Orphan Blood Diseases Market, Deal Segmentation by Geography 61
Figure 49: Inherited Orphan Blood Diseases Market, Deal Segmentation by Value 61
Figure 50: Inherited Orphan Blood Diseases Market, Deal Segmentation by Deal Type 62
Figure 51: GBI Research Market Forecasting Model 69